Sleep-Wake Disorders

Stroke recovery lasts years; learn why fatigue, sleep, hormones and cognition demand ongoing rehab beyond 90 days—and how progress can continue.

Learn more about the effect of sleep on coaches and athletic teams.

Phase 2 trial of oveporexton for narcolepsy type 1 finds improvement on measures of cognition, in addition to previously demonstrated improved hallmark symptom of nighttime wakefulness.

New initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 and type 2.

Elite coaches often run on severe sleep loss, risking impaired decisions, emotion control, and leadership.

New Sleep in America poll reveals kids fall short on sleep, parents underestimate needs, and family wellbeing suffers.

FDA grants priority review to Takeda’s orexin agonist oveporexton, promising phase 3 gains in wakefulness and cataplexy for narcolepsy type 1.

Sleep is vital for athlete patients, enhancing performance, mental health, and recovery. Discover effective strategies to optimize sleep for peak athletic success.

Seltorexant shows promise as a safe adjunctive treatment for patients with major depressive disorder and insomnia symptoms, with fewer weight changes than quetiapine XR.

The FDA has granted Breakthrough Therapy designation to Alkermes' alixorexton for narcolepsy type 1, which could offer hope for improved wakefulness and reduced daytime sleepiness.

Tris Pharma's TRN-257, a low-sodium oxybate, offers a once-nightly treatment option for narcolepsy and idiopathic hypersomnia, enhancing patient care.

Explore the complexities of insomnia treatment, highlighting the limited role of melatonin and the effectiveness of cognitive behavioral therapy for better sleep.

Alixorexton shows promising results in improving wakefulness and reducing daytime sleepiness in patients with narcolepsy type 2.

Explore the complexities of insomnia in older adults, its impact on health, and effective management strategies for improved sleep quality.

Discover the most effective components of cognitive behavioral therapy for chronic insomnia, enhancing treatment outcomes and patient care strategies.

Sleep disruption undermines team coordination in sports, revealing its critical role in collective performance and strategic success.

A new study reveals tasimelteon (Hetlioz) significantly improves sleep onset in chronic insomnia patients.

New phase 3 data reveals seltorexant's potential as a safer adjunctive treatment for major depressive disorder with insomnia, despite not meeting its primary end point.

Cognitive behavioral therapy for insomnia effectively treats chronic insomnia, promoting long-term sleep improvement through targeted behavioral strategies.

Takeda's oveporexton shows promising results in treating narcolepsy type 1, significantly improving symptoms and quality of life in clinical trials.

Alixorexton shows promise as a treatment for narcolepsy type 1, and is the first orexin 2 receptor agonist to demonstrate clinically meaningful and statistically significant impact on wakefulness, cognition, and fatigue with once-daily dosing across a range of doses.

Explore effective strategies for managing narcolepsy, including personalized treatment plans, medication options, and lifestyle interventions for improved patient outcomes.

Discover the complexities of sleep-related eating disorder, its symptoms, triggers, and effective treatments for better sleep health.

Apnimed reveals promising results for AD109, a groundbreaking oral treatment for obstructive sleep apnea.

Positive phase 2 results show that treatment with alixorexton led to statistically significant and dose-dependent improvements in sleep latency among patients with narcolepsy type 1.